Sophia Steinlein
Overview
Explore the profile of Sophia Steinlein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
11
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kurz K, Steinlein S, Kreuz M, Ziepert M, Staiger A, Barth T, et al.
Hemasphere
. 2025 Mar;
9(3):e70093.
PMID: 40060117
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Despite a high cure rate, too many patients show refractory (ref) or relapsed (rel) disease. This study examines the...
2.
Steinlein S, Essmann F, Ghilardi A, Horn H, Schuler J, Hausser A, et al.
Front Oncol
. 2023 Jun;
13:1190988.
PMID: 37305581
Introduction: Malignant pleural mesothelioma (MPM) is a neoplasm with dismal prognosis and notorious resistance to the standard therapeutics cisplatin and pemetrexed. Chalcone derivatives are efficacious anti-cancer agents with minimal toxicity...
3.
Kurz K, Ott M, Kalmbach S, Steinlein S, Kalla C, Horn H, et al.
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190213
The family/class of the large B-cell lymphomas (LBCL) in the 5th edition of the World Health Organization (WHO) classification of haematolymphoid tumors (WHO-HAEM5) features only a few major changes as...
4.
Aschmoneit N, Steinlein S, Kuhl L, Seifert O, Kontermann R
Sci Rep
. 2021 Jul;
11(1):13880.
PMID: 34230555
HER3 is a member of the EGF receptor family and elevated expression is associated with cancer progression and therapy resistance. HER3-specific T-cell engagers might be a suitable treatment option to...